StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly Acquired in-process research and development charges by Quarter

Acquired in-process research and development (IPR&D) charges ($M) ($M)

QuarterlyAnnual

Eli Lilly Acquired in-process research and development charges: $2,776M in Q2 2026, up 1,702.6% from a year earlier.

Latest, Q2 2026
2,776
Period ended Jun 30, 2026
Change on a year earlier
+1,702.6%
154 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Note 3.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAcquired in-process research and development (IPR&D) charges ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20262,776+1,702.6%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026584-62.8%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025529+180.1%Form 10-K (filed 2026-02-12) ↗
Q3 2025Sep 30, 2025656-76.8%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 2025154-0.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20251,572+1,322.6%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 2024189-69.5%Form 10-K (filed 2026-02-12) ↗
Q3 2024Sep 30, 20242,826-5.2%Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 2024154+58.9%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024111+5.2%Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 2023620+158.2%Form 10-K (filed 2026-02-12) ↗
Q3 2023Sep 30, 20232,980+4,675.6%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 202397.1-78.0%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023105-36.6%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022240-49.1%Form 10-K (filed 2025-02-19) ↗
Q3 2022Sep 30, 202262.4-64.1%Form 10-Q (filed 2023-11-02) ↗

Breakdown

What makes up acquired in-process research and development charges

Cite this data

StockData. (2026). Eli Lilly Acquired in-process research and development charges ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/iprd-charges

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.